FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256670191> ?p ?o ?g. }

• W4256670191 endingPage "39" @default.
• W4256670191 startingPage "33" @default.
• W4256670191 abstract "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in accordance with the licensed indication, based upon the evidence submission from the manufacturer (Eli Lilly) to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The primary clinical outcome measure was progression free survival (PFS). Secondary outcomes included overall survival (OS), time to worsening of symptoms, objective tumour response rate, adverse events and changes in lung cancer symptom scale. Data for two populations were presented: patients with non-squamous NSCLC histology and patients with adenocarcinoma histology. The clinical evidence was derived from a double-blind, placebo-controlled randomised controlled trial (RCT), the JMEN trial. The trial compared the use of pemetrexed + best supportive care (BSC ) as maintenance therapy, with placebo + BSC in patients with NSCLC ( n = 663) who had received four cycles of platinum-based chemotherapy (CTX) and whose disease had not progressed. In the licensed population (patients with non-squamous histology), the trial demonstrated greater median PFS for patients treated with pemetrexed than for patients in the placebo arm [4.5 vs 2.6 months; hazard ratio (HR) 0.44; 95% confidence interval (CI) 0.36 to 0.55, p < 0.00001]. Median OS was also greater for the pemetrexed- treated patients (15.5 vs 10.3 months; HR 0.70; 95% CI 0.56 to 0.88, p = 0.002). In addition, tumour response and disease control rates were statistically significantly greater for patients who received pemetrexed. Patient survival rates at 1 year and 2 years were higher in the pemetrexed arm. The incremental cost-effectiveness ratios (ICERs) estimated by the manufacturer’s model were £33,732 per quality adjusted life-year (QALY) for the licensed nonsquamous population, and £39,364 per QALY for the adenocarcinoma subgroup. Both of these ICERs were above the standard NICE willingness-to-pay range (£20,000–£30,000 per QALY). The manufacturer also presented a case for pemetrexed to be considered as an end of life treatment. The ERG identified a number of problems in the economic model presented by the manufacturer; after correction, the base case ICER was re-estimated as £51,192 per QALY gained and likely to exceed NICE’s willingness-to-pay thresholds. Following a revised economic analysis submitted by the manufacturer, the AC accepted that an ICER of £47,000 per QALY gained was most plausible. The AC also considered that maintenance treatment with pemetrexed fulfilled the end of life criteria.The guidance issued by NICE, on 20 June 20 2010, in TA190 as a result of the STA states that: People who have received pemetrexed in combination with cisplatin as first-line chemotherapy cannot receive pemetrexed maintenance treatment. 1.1 Pemetrexed is recommended as an option for the maintenance treatment of people with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology if disease has not progressed immediately following platinum-based chemotherapy in combination with gemcitabine, paclitaxel or docetaxel." @default.
• W4256670191 created "2022-05-12" @default.
• W4256670191 creator A5011624664 @default.
• W4256670191 creator A5041932491 @default.
• W4256670191 creator A5049004669 @default.
• W4256670191 creator A5058647212 @default.
• W4256670191 creator A5068090235 @default.
• W4256670191 creator A5068763092 @default.
• W4256670191 creator A5070784630 @default.
• W4256670191 creator A5071190566 @default.
• W4256670191 creator A5079476800 @default.
• W4256670191 creator A5079590143 @default.
• W4256670191 creator A5084858270 @default.
• W4256670191 creator A5088883248 @default.
• W4256670191 date "2010-10-01" @default.
• W4256670191 modified "2023-10-12" @default.
• W4256670191 title "Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer" @default.
• W4256670191 cites W1593173821 @default.
• W4256670191 cites W2023758807 @default.
• W4256670191 cites W2065746026 @default.
• W4256670191 cites W2112621029 @default.
• W4256670191 doi "https://doi.org/10.3310/hta14suppl2-05" @default.
• W4256670191 hasPublicationYear "2010" @default.
• W4256670191 type Work @default.
• W4256670191 citedByCount "8" @default.
• W4256670191 countsByYear W42566701912015 @default.
• W4256670191 countsByYear W42566701912017 @default.
• W4256670191 countsByYear W42566701912018 @default.
• W4256670191 countsByYear W42566701912019 @default.
• W4256670191 countsByYear W42566701912020 @default.
• W4256670191 crossrefType "journal-article" @default.
• W4256670191 hasAuthorship W4256670191A5011624664 @default.
• W4256670191 hasAuthorship W4256670191A5041932491 @default.
• W4256670191 hasAuthorship W4256670191A5049004669 @default.
• W4256670191 hasAuthorship W4256670191A5058647212 @default.
• W4256670191 hasAuthorship W4256670191A5068090235 @default.
• W4256670191 hasAuthorship W4256670191A5068763092 @default.
• W4256670191 hasAuthorship W4256670191A5070784630 @default.
• W4256670191 hasAuthorship W4256670191A5071190566 @default.
• W4256670191 hasAuthorship W4256670191A5079476800 @default.
• W4256670191 hasAuthorship W4256670191A5079590143 @default.
• W4256670191 hasAuthorship W4256670191A5084858270 @default.
• W4256670191 hasAuthorship W4256670191A5088883248 @default.
• W4256670191 hasBestOaLocation W42566701911 @default.
• W4256670191 hasConcept C126322002 @default.
• W4256670191 hasConcept C141071460 @default.
• W4256670191 hasConcept C143998085 @default.
• W4256670191 hasConcept C168563851 @default.
• W4256670191 hasConcept C197934379 @default.
• W4256670191 hasConcept C207103383 @default.
• W4256670191 hasConcept C2776256026 @default.
• W4256670191 hasConcept C2776694085 @default.
• W4256670191 hasConcept C2776907518 @default.
• W4256670191 hasConcept C2777240266 @default.
• W4256670191 hasConcept C2778239845 @default.
• W4256670191 hasConcept C2908647359 @default.
• W4256670191 hasConcept C44249647 @default.
• W4256670191 hasConcept C535046627 @default.
• W4256670191 hasConcept C71924100 @default.
• W4256670191 hasConcept C99454951 @default.
• W4256670191 hasConceptScore W4256670191C126322002 @default.
• W4256670191 hasConceptScore W4256670191C141071460 @default.
• W4256670191 hasConceptScore W4256670191C143998085 @default.
• W4256670191 hasConceptScore W4256670191C168563851 @default.
• W4256670191 hasConceptScore W4256670191C197934379 @default.
• W4256670191 hasConceptScore W4256670191C207103383 @default.
• W4256670191 hasConceptScore W4256670191C2776256026 @default.
• W4256670191 hasConceptScore W4256670191C2776694085 @default.
• W4256670191 hasConceptScore W4256670191C2776907518 @default.
• W4256670191 hasConceptScore W4256670191C2777240266 @default.
• W4256670191 hasConceptScore W4256670191C2778239845 @default.
• W4256670191 hasConceptScore W4256670191C2908647359 @default.
• W4256670191 hasConceptScore W4256670191C44249647 @default.
• W4256670191 hasConceptScore W4256670191C535046627 @default.
• W4256670191 hasConceptScore W4256670191C71924100 @default.
• W4256670191 hasConceptScore W4256670191C99454951 @default.
• W4256670191 hasFunder F4320334661 @default.
• W4256670191 hasIssue "Suppl 2" @default.
• W4256670191 hasLocation W42566701911 @default.
• W4256670191 hasOpenAccess W4256670191 @default.
• W4256670191 hasPrimaryLocation W42566701911 @default.
• W4256670191 hasRelatedWork W10130044 @default.
• W4256670191 hasRelatedWork W12636511 @default.
• W4256670191 hasRelatedWork W14327771 @default.
• W4256670191 hasRelatedWork W16128638 @default.
• W4256670191 hasRelatedWork W20217714 @default.
• W4256670191 hasRelatedWork W21174161 @default.
• W4256670191 hasRelatedWork W2507035 @default.
• W4256670191 hasRelatedWork W3197746 @default.
• W4256670191 hasRelatedWork W4133181 @default.
• W4256670191 hasRelatedWork W7348958 @default.
• W4256670191 hasVolume "14" @default.
• W4256670191 isParatext "false" @default.
• W4256670191 isRetracted "false" @default.
• W4256670191 workType "article" @default.